Loading…
Fulgent Genetics, Inc. is projected to rise to $20.07 by 2027, a +12% move from its current price of $17.90. FLGT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $17.46 | $17.90 | $18.36 | +0.02% |
| May 30 | $17.28 | $17.91 | $18.56 | +0.04% |
| May 31 | $17.15 | $17.91 | $18.71 | +0.06% |
| Jun 1 | $17.04 | $17.91 | $18.84 | +0.08% |
| Jun 2 | $16.94 | $17.92 | $18.96 | +0.10% |
| Jun 3 | $16.85 | $17.92 | $19.06 | +0.12% |
| Jun 4 | $16.77 | $17.93 | $19.16 | +0.15% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $16.77 | $17.93 | $19.16 | +0.15% |
| Week 2 | $16.34 | $17.95 | $19.72 | +0.29% |
| Week 3 | $16.02 | $17.98 | $20.17 | +0.44% |
| Week 4 | $15.76 | $18.00 | $20.57 | +0.58% |
| Week 5 | $15.54 | $18.03 | $20.92 | +0.73% |
| Week 6 | $15.34 | $18.06 | $21.25 | +0.87% |
| Week 7 | $15.16 | $18.08 | $21.56 | +1.02% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally.
Its clinical diagnostic solutions include molecular diagnostic testing, genetic testing, anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencing services related to hereditary cancer, reproductive health, and other diseases.
Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates the picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients.
Fulgent Genetics, Inc. was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.
Fulgent Genetics, Inc. (FLGT) is a healthcare company trading in the market with a current price of $17.11 per share and a market capitalization of $485.93M. It is ranked 3057 by market cap.
The stock carries a multi-year forecast that projects meaningful upside, with the average forecast price rising to $28.80 by 2030 and to $116.56 by 2050, reflecting a long-term bullish outlook. The forecast also shows evolving returns over time, starting from a neutral stance in 2026 and strengthening to substantial gains by 2030 and beyond.
A major floor 28.1% below — a decisive break under it would weaken the trend.
The nearest floor, 21.1% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 57.4% above — clearing it would confirm fresh momentum.
Key FLGT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of FLGT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $17.29 | Buy | $17.31 | Buy |
| MA 10 | $16.61 | Buy | $16.81 | Buy |
| MA 20 | $15.89 | Buy | $16.35 | Buy |
| MA 50 | $15.89 | Buy | $16.73 | Buy |
| MA 100 | $19.44 | Sell | $18.49 | Sell |
| MA 200 | $21.96 | Sell | $20.08 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 66.31 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 178.63 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.28 | Buy |
| ROC (12) | 12.16 | Buy |
| Bollinger %B (20,2) | 1.01 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.13 | Buy |
| Awesome (5,34) | 1.45 | Buy |
| Ultimate (7,14,28) | 82.99 | Sell |
| Momentum (10) | 2.10 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 17.95 | Sell |
| ADX (14) | 15.26 | Neutral |
| ATR (14) | 0.39 | Info |
The near-term technical picture is described as BULLISH in the data, with RSI14 at 60 and price action supported by a 30-day range between $14.44 and $20.28. The SMA50 stands at $15.78, while the SMA200 sits at $21.99, providing nearby reference points for momentum and trend direction. A key support level is $14.13 and a resistance level is $17.38, framing a near-term path for FLGT as it traverses the current price environment.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $13.79 | $17.90 | $23.86 | 0% | Neutral | |
| $16.04 | $20.07 | $26.53 | +12% | Neutral | |
| $17.44 | $22.36 | $30.56 | +25% | Bullish | |
| $19.52 | $25.57 | $35.87 | +43% | Bullish | |
| $23.30 | $31.08 | $44.60 | +74% | Bullish | |
| $24.65 | $33.43 | $48.92 | +87% | Bullish | |
| $25.20 | $34.72 | $51.71 | +94% | Bullish | |
| $27.20 | $38.02 | $57.54 | +112% | Bullish | |
| $26.23 | $37.18 | $57.10 | +108% | Bullish | |
| $29.05 | $41.72 | $64.97 | +133% | Bullish | |
| $38.32 | $58.44 | $96.42 | +226% | Bullish | |
| $76.52 | $129.29 | $232.20 | +622% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $13.79 | $17.90 | $21.09 | +0.00% |
| June 2026 | $15.71 | $18.42 | $22.08 | +2.89% |
| July 2026 | $15.44 | $18.24 | $22.15 | -0.95% |
| August 2026 | $15.46 | $18.38 | $22.53 | +0.76% |
| September 2026 | $15.92 | $19.02 | $23.49 | +3.48% |
| October 2026 | $15.88 | $19.06 | $23.71 | +0.20% |
| November 2026 | $15.48 | $18.66 | $23.35 | -2.10% |
| December 2026 | $15.67 | $18.95 | $23.86 | +1.57% |
Click any year to see its month-by-month FLGT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, FLGT is projected to trade between $13.79 and $23.86, averaging $17.90 — a potential gain of 0% from today's $17.90. Price action looks broadly range-bound.
Fulgent Genetics, Inc.'s 2027 outlook centres on $20.07, within a $16.04 to $26.53 range. That is up +12% on the projected 2026 average. That marks a +12% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, FLGT could reach as high as $30.56, with a base case around $22.36 and support toward $17.44 — roughly +25% from $17.90. Momentum favours further upside here.
Expect FLGT to range from $19.52 to $35.87 through 2029. The $25.57 average target implies a +43% move from current prices. That is up +14% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The FLGT price prediction for 2030 points to an average of $31.08 (low $23.30, high $44.60) — a potential gain of +74% on today's $17.90. Momentum favours further upside here.
In 2031, FLGT is projected to trade between $24.65 and $48.92, averaging $33.43 — a potential gain of +87% from today's $17.90. That is up +8% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Fulgent Genetics, Inc.'s 2032 outlook centres on $34.72, within a $25.20 to $51.71 range. That is up +4% on the projected 2031 average. That marks a +94% change versus current levels. Momentum favours further upside here.
By 2033, FLGT could reach as high as $57.54, with a base case around $38.02 and support toward $27.20 — roughly +112% from $17.90. Buyers look set to stay in control over this stretch.
Expect FLGT to range from $26.23 to $57.10 through 2034. The $37.18 average target implies a +108% move from current prices. That is -2% versus the projected 2033 average. Momentum favours further upside here.
The FLGT price prediction for 2035 points to an average of $41.72 (low $29.05, high $64.97) — a potential gain of +133% on today's $17.90. Buyers look set to stay in control over this stretch.
In 2040, FLGT is projected to trade between $38.32 and $96.42, averaging $58.44 — a potential gain of +226% from today's $17.90. That is up +40% on the projected 2035 average. Momentum favours further upside here.
Fulgent Genetics, Inc.'s 2050 outlook centres on $129.29, within a $76.52 to $232.20 range. That is up +121% on the projected 2040 average. That marks a +622% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in FLGT today (≈ 55.865922 FLGT) could be worth
$7,223.17
+$6,223.17 (+622%) by 2050 · US Dollar
Based on the average projected FLGT price of $129.29 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in FLGTwould be worth at today's price.
$1,000 invested in FLGT on May 27, 2025 (≈ 49.529469 FLGT) would be worth
$886.58
-$113.42 (-11.3%) today · 0.89× · US Dollar
Based on a FLGT entry price of $20.19 vs. today's $17.9.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $16.41 | $1,090.8 | +9.1% |
| 1 month ago | $15.6 | $1,147.44 | +14.7% |
| 3 months ago | $24.76 | $722.94 | -27.7% |
| 6 months ago | $29.58 | $605.14 | -39.5% |
| 1 year ago | $20.19 | $886.58 | -11.3% |
| All time (5.0y) ago | $69.24 | $258.52 | -74.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our FLGT forecast.
Our base-case forecast reaches $36.00 around 2033.
Implied market cap at $36.00: $1.02B
Viewing the multi-year forecast, FLGT shows a clear progression in price expectations. For 2026, the average price is $17.11 with a neutral sentiment and a 0% ROI, illustrating a starting point in the forecast window. By 2030, the average price is projected to $28.80 with a bullish sentiment and a 68.3% ROI, signaling rising investor confidence over time.
In 2040, the forecast envisions an average of $52.71 and a 208.1% ROI, continuing the bullish trajectory. By 2050, the average price is $116.56 with a 581.2% ROI and a bullish sentiment, indicating substantial long-term upside potential. These are estimates, not guarantees, and should be considered within the broader context of investment risk and market dynamics.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $28.80, with a min of $21.50 and a max of $41.53, and an ROI of 68.3%, with a bullish sentiment.
The forecast indicates rising average prices through 2030–2050 with increasing ROIs (2030 68.3%, 2040 208.1%, 2050 581.2%), and bullish sentiment in later years, but these are estimates and not guarantees.
Yes. The 2040 max price is $87.61, and the 2040 average is $52.71, indicating scenarios where the price exceeds $50 during the forecast horizon.
The 30-day range is $14.44 to $20.28, with RSI14 at 60, SMA50 at $15.78, SMA200 at $21.99, a support level of $14.13, and a resistance level of $17.38.
Key milestones include 2030 average $28.80 with 68.3% ROI, 2040 average $52.71 with 208.1% ROI, and 2050 average $116.56 with 581.2% ROI, all with bullish sentiment.
Fulgent Genetics, Inc. Community Discussion
0Share your Fulgent Genetics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.